Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.15 | -0.06 | 1.01 |
| FCF Yield | -11.34% | -13.02% | -10.22% | -3.43% |
| EV / EBITDA | -8.08 | -4.87 | -8.95 | -29.36 |
| Quality | ||||
| ROIC | -11.76% | -14.47% | -13.98% | -10.81% |
| Gross Margin | 97.91% | 5.48% | -0.85% | 38.20% |
| Cash Conversion Ratio | 0.86 | 0.60 | 0.89 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 607.54% | 904.91% | 5,968,981.69% | 5,474,371.22% |
| Free Cash Flow Growth | -19.54% | 31.84% | -41.88% | -26.45% |
| Safety | ||||
| Net Debt / EBITDA | 1.25 | 0.78 | 1.10 | 0.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.03 | 1.14 | 0.76 | 0.88 |
| Cash Conversion Cycle | 1,397.72 | 118.30 | 196.49 | 132.13 |